Management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (COVID-19) epidemic

COVID-19 has become a pandemic and it has already spread to at least 171 countries/regions. Chronic kidney disease (CKD) is a global public health problem with a total of approximately 850 million patients with CKD worldwide and 119.5 million in China. Severe COVID-19 infection may damage the kidney...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Juan Li, Shuang-Xi Li, Li-Fang Zhao, De-Liang Kong, Zhi-Yong Guo
Formato:	article
Lenguaje:	EN
Publicado:	KeAi Communications Co., Ltd. 2020
Materias:	Coronavirus disease 2019 COVID-19 Novel coronavirus Chronic kidney disease Management Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/b422c05ebc4e4a76b952dabeaca85184
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b422c05ebc4e4a76b952dabeaca85184
record_format	dspace
spelling	oai:doaj.org-article:b422c05ebc4e4a76b952dabeaca851842021-12-02T13:45:43ZManagement recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (COVID-19) epidemic2095-882X10.1016/j.cdtm.2020.05.001https://doaj.org/article/b422c05ebc4e4a76b952dabeaca851842020-06-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2095882X20300402https://doaj.org/toc/2095-882XCOVID-19 has become a pandemic and it has already spread to at least 171 countries/regions. Chronic kidney disease (CKD) is a global public health problem with a total of approximately 850 million patients with CKD worldwide and 119.5 million in China. Severe COVID-19 infection may damage the kidney and cause acute tubular necrosis, leading to proteinuria, hematuria and elevated serum creatinine. Since the SARS-CoV-2 enters the cells by binding to the angiotensin-converting enzyme 2 receptor, some doctors question its ability to increase the risk and severity of developing COVID-19. Neither clinical data nor basic scientific evidence supports this assumption. Therefore, patients who take angiotensin-converting enzyme inhibitor or angiotensin receptor blocker are not advised to change their therapy. Patients with CKD are generally the elderly population suffering from multiple comorbidities. Moreover, some patients with CKD might need to take glucocorticoids and immunosuppressants. Dialysis patients are recurrently exposed to a possible contaminated environment because their routine treatment usually requires three dialysis sessions per week. Considering all the above reasons, patients with CKD are more vulnerable to COVID-19 than the general population. The development of COVID-19 may worsen the impaired kidney function and further lead to rapid deterioration of kidney function and even death. Strict comprehensive protocols should be followed to prevent the spread of COVID-19 among patients with CKD. In this review, we provide some practical management recommendations for health care providers, patients with CKD, dialysis patients and dialysis facilities.Juan LiShuang-Xi LiLi-Fang ZhaoDe-Liang KongZhi-Yong GuoKeAi Communications Co., Ltd.articleCoronavirus disease 2019COVID-19Novel coronavirusChronic kidney diseaseManagementMedicine (General)R5-920ENChronic Diseases and Translational Medicine, Vol 6, Iss 2, Pp 119-123 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Coronavirus disease 2019 COVID-19 Novel coronavirus Chronic kidney disease Management Medicine (General) R5-920
spellingShingle	Coronavirus disease 2019 COVID-19 Novel coronavirus Chronic kidney disease Management Medicine (General) R5-920 Juan Li Shuang-Xi Li Li-Fang Zhao De-Liang Kong Zhi-Yong Guo Management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (COVID-19) epidemic
description	COVID-19 has become a pandemic and it has already spread to at least 171 countries/regions. Chronic kidney disease (CKD) is a global public health problem with a total of approximately 850 million patients with CKD worldwide and 119.5 million in China. Severe COVID-19 infection may damage the kidney and cause acute tubular necrosis, leading to proteinuria, hematuria and elevated serum creatinine. Since the SARS-CoV-2 enters the cells by binding to the angiotensin-converting enzyme 2 receptor, some doctors question its ability to increase the risk and severity of developing COVID-19. Neither clinical data nor basic scientific evidence supports this assumption. Therefore, patients who take angiotensin-converting enzyme inhibitor or angiotensin receptor blocker are not advised to change their therapy. Patients with CKD are generally the elderly population suffering from multiple comorbidities. Moreover, some patients with CKD might need to take glucocorticoids and immunosuppressants. Dialysis patients are recurrently exposed to a possible contaminated environment because their routine treatment usually requires three dialysis sessions per week. Considering all the above reasons, patients with CKD are more vulnerable to COVID-19 than the general population. The development of COVID-19 may worsen the impaired kidney function and further lead to rapid deterioration of kidney function and even death. Strict comprehensive protocols should be followed to prevent the spread of COVID-19 among patients with CKD. In this review, we provide some practical management recommendations for health care providers, patients with CKD, dialysis patients and dialysis facilities.
format	article
author	Juan Li Shuang-Xi Li Li-Fang Zhao De-Liang Kong Zhi-Yong Guo
author_facet	Juan Li Shuang-Xi Li Li-Fang Zhao De-Liang Kong Zhi-Yong Guo
author_sort	Juan Li
title	Management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (COVID-19) epidemic
title_short	Management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (COVID-19) epidemic
title_full	Management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (COVID-19) epidemic
title_fullStr	Management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (COVID-19) epidemic
title_full_unstemmed	Management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (COVID-19) epidemic
title_sort	management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (covid-19) epidemic
publisher	KeAi Communications Co., Ltd.
publishDate	2020
url	https://doaj.org/article/b422c05ebc4e4a76b952dabeaca85184
work_keys_str_mv	AT juanli managementrecommendationsforpatientswithchronickidneydiseaseduringthenovelcoronavirusdisease2019covid19epidemic AT shuangxili managementrecommendationsforpatientswithchronickidneydiseaseduringthenovelcoronavirusdisease2019covid19epidemic AT lifangzhao managementrecommendationsforpatientswithchronickidneydiseaseduringthenovelcoronavirusdisease2019covid19epidemic AT deliangkong managementrecommendationsforpatientswithchronickidneydiseaseduringthenovelcoronavirusdisease2019covid19epidemic AT zhiyongguo managementrecommendationsforpatientswithchronickidneydiseaseduringthenovelcoronavirusdisease2019covid19epidemic
_version_	1718392517891719168

Management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (COVID-19) epidemic

Ejemplares similares